Vinblastine
- Generic Name
- Vinblastine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C46H58N4O9
- CAS Number
- 865-21-4
- Unique Ingredient Identifier
- 5V9KLZ54CY
- Background
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
- Indication
For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.
- Associated Conditions
- Advanced Soft Tissue Sarcoma, Autoimmune Hemolytic Anemia, Bladder Cancer, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Letterer-Siwe disease, Metastatic Melanoma, Non-Small Cell Lung Cancer (NSCLC), Advanced Alibert-Bazin syndrome, Advanced Testicular cancer, Histiocytic lymphoma, Refractory Breast cancer
- Associated Therapies
- -
Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2008-12-16
- Last Posted Date
- 2016-10-24
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 39
- Registration Number
- NCT00808639
- Locations
- πΊπΈ
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
πΊπΈLahey Clinic, Burlington, Massachusetts, United States
πΊπΈUniversity of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 58
- Registration Number
- NCT00654732
- Locations
- πΊπΈ
Rush University Medical Center, Chicago, Illinois, United States
πΊπΈM D Anderson Cancer Center, Houston, Texas, United States
πΊπΈMemorial Sloan Kettering Cancer Center, New York, New York, United States
Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2015-10-08
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 41
- Registration Number
- NCT00635726
- Locations
- π¬π·
IASO General Hospital of Athens, 1st Dept. of Medical Oncology, Athens, Greece
π¬π·University General Hospital of Alexandroupolis, Dept. of Medical Oncology, Alexandroupolis, Greece
π¬π·Metaxa's Anticancer Hospital of Piraeus, 1st Dept. of Medical Oncology, Piraeus, Greece
Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)
- First Posted Date
- 2007-12-18
- Last Posted Date
- 2017-09-20
- Lead Sponsor
- The Hospital for Sick Children
- Target Recruit Count
- 50
- Registration Number
- NCT00575796
- Locations
- π¨π¦
Saskatoon Cancer Center, Saskatoon, Saskatchewan, Canada
π¨π¦Children's and Women's Health Centre of British Columbia, Vancouver, British Columbia, Canada
π¨π¦IWK Health Centre, Halifax, Nova Scotia, Canada
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.
- Conditions
- Interventions
- First Posted Date
- 2007-08-24
- Last Posted Date
- 2014-10-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 25
- Registration Number
- NCT00520403
Gene Expression Profiling in Patients With Invasive Bladder Cancer Receiving Methotrexate, Vinblastine, Doxorubicin, and Cisplatin
- Conditions
- First Posted Date
- 2007-08-15
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- Kyoto University
- Target Recruit Count
- 100
- Registration Number
- NCT00516750
- Locations
- π―π΅
Shiga Medical Center for Adults, Moriyama, Shiga, Japan
π―π΅Nagoya University Hospital, Nagoya, Aichi, Japan
π―π΅Kyoto University Hospital, Kyoto, Japan
PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2007-08-08
- Last Posted Date
- 2015-12-03
- Lead Sponsor
- University of Cologne
- Registration Number
- NCT00512980
- Locations
- π©πͺ
University of Cologne, Cologne, Germany
Rituximab and ABVD for Hodgkin's Patients
- Conditions
- Interventions
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2013-07-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 85
- Registration Number
- NCT00504504
- Locations
- πΊπΈ
UT MD . Anderson Cancer Center, Houston, Texas, United States
Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers
- Conditions
- Interventions
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2020-07-24
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT00498979
- Locations
- πΊπΈ
Cleveland Clinic Taussig Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2018-08-27
- Target Recruit Count
- 51
- Registration Number
- NCT00369681
- Locations
- πΊπΈ
City of Hope Comprehensive Cancer Center, Duarte, California, United States
πΊπΈMayo Clinic Cancer Center, Rochester, Minnesota, United States
πΊπΈHolden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.